Cancer suppresses mitochondrial chaperone activity in macrophages to drive immune evasion
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE279754 | GEO | 2025/10/14
REPOSITORIES: GEO
Similar Datasets
Project description:Here we report that the Th2 cytokine IL-4 and the tumor microenvironment activated protein kinase RNA-like ER kinase (PERK) stress signaling cascade to promote immunosuppressive M2 activation and proliferation. PERK activation mediated the upregulation of PSAT1 and serine biosynthesis via the downstream transcription factor ATF4. We found that Increased serine biosynthesis could result in enhanced mitochondrial function and α-ketoglutarate (α-KG) production required for JMJD3-dependent epigenetic modification.
2022-01-01 | GSE183287 | GEO
Project description:The neonatal mammalian heart is capable of substantial regeneration following injury through cardiomyocyte proliferation. However, this regenerative capacity is lost by postnatal (P) day 7. How to stimulate the adult cardiomyocyte to re-enter the cell cycle is still unknown. Accumulating evidence suggests that cardiomyocyte proliferation depends on its metabolic state. Due to the tight connection between the tricarboxylic acid cycle (TCA) and cell proliferation, we analyzed the TCA metabolites between P0.5 and P7 mouse hearts and found that α-ketoglutarate (α-KG) ranked first among the decreased metabolites. The intraperitoneal injection of exogenous α-KG extended the window of cardiomyocyte proliferation during heart development and promoted heart regeneration after myocardial infarction (MI) by inducing adult cardiomyocyte proliferation. This was confirmed in Ogdh-siRNA-treated mice with increased α-KG levels. Mechanistically, α-KG activates Jmjd3, a histone lysine demethylase, that decreases H3K27me3 expression and deposition of H3K4me3 at the promoters of cell cycle and structural maturation genes in cardiomyocytes. Our present study shows that α-KG promotes cardiomyocyte proliferation by Jmjd3-dependent demethylation and inactivation of H3K27me3 andH3K4me3, which is a potential therapeutic approach for treating MI and heart failure.
2024-07-12 | GSE272104 | GEO
Project description:Protein homeostasis, or proteostasis is critical for organelle function, including mitochondria, but its role in cancer is controversial. Here, we show that transgenic mice expressing the mitochondrial chaperone, TRAP1 in the prostate develop prostatic hyperplasia and cellular atypia. When examined on a Pten+/- background, a common alteration in prostate cancer patients, TRAP1 transgenic mice showed accelerated incidence of invasive prostatic adenocarcinoma, characterized by increased cell proliferation and reduced apoptosis, in situ. Conversely, homozygous deletion of TRAP1 delays prostatic tumorigenesis in Pten+/- mice, without affecting hyperplasia or prostatic intraepithelial neoplasia (PIN). Global RNA sequencing and reverse phase protein array profiling of Pten+/--TRAP1 transgenic tumors reveals modulation of oncogenic networks of cell proliferation, apoptosis, cell motility, DNA damage and metabolism. Mechanistically, reconstitution of Pten+/- prostatic epithelial cells with TRAP1 results in increased cell proliferation, reduced apoptosis, heightened cell invasion, and no changes in mitochondrial bioenergetics. Therefore, TRAP1 promotes invasive prostate cancer, and provides an “actionable” therapeutic target in patients with advanced disease.
2017-05-11 | GSE81316 | GEO
Project description:Here we show that TRAP1 directly binds translation elongation factors, both inside and outside mitochondria, and slows down translation. TRAP1 overexpression or silencing affects the synthesis of respiratory complex components. Inside mitochondria, TRAP1 binds the Complex III core component UQCRC2 and regulates Complex III activity. This decreases respiration rate upon basal condition but allows sustained oxidative phosphorylation when glucose is limiting, a condition in which TRAP1-UQCRC2 binding is lost. In humans, TRAP1 is co-expressed with the mitochondrial translational machinery, which synthesize respiratory complex proteins. Altogether, our results show an unprecedented level of complexity in the regulation of cancer cell metabolism, in which mitochondrial and cytosolic protein synthesis are co-regulated with energetic metabolism through the contribution of a common molecular chaperone
2023-12-07 | GSE141616 | GEO
Project description:2-hydroxyglutarate (2-HG) is an oncometabolite accumulating in certain cancers and some neurometabolic diseases. In cancers 2-HG accumulation is induced by a gain-of-function mutation in isocitrate dehydrogenase (IDH) genes, leading to conversion of alpha-ketoglutarate (a-KG) into 2-HG
2023-04-15 | E-MTAB-11328 | biostudies-arrayexpress
Project description:Metabolic adaptations can sustain the pro-neoplastic functions exerted by macrophages in the tumor microenvironment. Malignant peripheral nerve sheath tumors (MPNSTs), aggressive and incurable sarcomas that develop either sporadically or in the context of the genetic syndrome Neurofibromatosis type 1, are highly infiltrated by macrophages, whose contribution to MPNST growth remains poorly characterized. Here, we analyze the role played by the molecular chaperone TRAP1, a regulator of mitochondrial metabolic pathways, in shaping the pro-tumoral activity of macrophages associated to MPNST cells. We have studied the phenotypic changes elicited by a MPNST cell-conditioned medium in macrophages with or without TRAP1, and their subsequent ability to support MPNST cell growth and migration and endothelial cell angiogenesis. The presence of TRAP1 is required in both naive and M2-like macrophages for eliciting phenotypic changes that lead to the acquisition of pro-neoplastic features. TRAP1-expressing macrophages become able to sustain MPNST cell growth and migration and to exert pro-angiogenic properties on endothelial cells through accumulation of the metabolite succinate and the ensuing activation of a HIF-1α-dependent transcriptional program. Our data provide evidence of a molecular crosstalk between MPNST cellular components, in which soluble factors released by cancer cells drive phenotypic changes in macrophages that in turn enhance pro-tumoral biological routines in both MPNST and endothelial cells. TRAP1-dependent metabolic rewiring in macrophages is mandatory for sustaining this interplay, as a TRAP1-succinate-HIF-1α signaling axis orchestrates their acquisition of tumor-promoting features.
2025-09-03 | GSE293735 | GEO
Project description:There is growing evidence of mitochondrial disturbance in autism spectrum disorders (ASD) but causative relations remain to be established. We identified postzygotic mozaicp.Q639* mutation in the TRAP1 gene encoding mitochondrial chaperone of the HSP90 family in ASD patient whose monozygotic twin brother was healthy. An additional survey of 176 unrelated ASD probands showed identical TRAP1 variant in a single male patient. We generated a knock-in Trap1 p.Q641*mouse which displayed behavioral abnormalities relevant for ASD, that were more pronounced in males. This effect was corroborated by gender-specific differences in synaptic plasticity and the density of synaptic mitochondria. Next we performed transcriptome profiling by sequencing of RNA isolated from hippocampi of WT, HET and MUT male and female mice
2024-03-01 | GSE226319 | GEO
Project description:Immune-response gene 1 (IRG1) transcription is rapidly induced by pathogen infections and inflammatory conditions primarily in cells of myeloid lineage. Deletion of Irg1 in mice causes severe defects in response to bacterial and viral infection and rapid death. IRG1 encodes a mitochondrial metabolic enzyme, aconitate decarboxylase 1 (ACOD1), that catalyzes the decarboxylation of cis-aconitate, a tricarboxylic acid cycle intermediate, to produce the anti-inflammatory metabolite itaconic acid (ITA). ITA can inhibit SDH5, resulting in elevated levels of succinate and metabolic reprogramming, or alkylate protein cysteine residues to induce electrophilic stress response mediated by NRF2 and IκBζ. Here we show that ITA is an antagonist of α-ketoglutarate (α-KG) and a potent inhibitor of α-KG/Fe2+-dependent TET family of DNA dioxygenases. In vitro, ITA binds to TET2 and inhibits the catalytic activity of TET2 and, reciprocally, α-KG blocks ITA binding to and inhibition of TET2. In vivo, lipopolysaccharides (LPS) treatment, which induces IRG1 expression and causes the intracellular accumulation of ITA, inhibits TET activity in Irg1-WT, but not Irg1-KO macrophages. Moreover, TET2 is a major target of ITA function in suppressing LPS-induced genes. LPS stimulates p65 NF-κB/RelA to bind with and recruit TET2 to hydroxymethylate and activate the Nfkbiz gene, which encodes IκBζ. Our results thus identify a physiological metabolite inhibitor of TET enzymes and reveal a novel mechanism for the anti-inflammatory function of ITA through dampening TET2-mediated NF-κB signaling.
2022-01-10 | GSE158580 | GEO
Project description:In recent years, gastric cancer (GC) has garnered significant attention due to its poor response to treatment, unfavorable prognosis, and the lack of reliable biomarkers for predicting disease progression and therapeutic outcomes. α-Ketoglutarate (α-KG), a critical metabolite involved in cellular energy metabolism and epigenetic regulation during tumor development, has emerged as a potential prognostic biomarker for GC. To explore this potential, we utilized publicly available datasets from the TCGA and GEO databases to analyze α-KG-related genes and establish the α-KG Index (AKGI). By evaluating the predictive performance of the AKGI model, we confirmed its robust capability to predict survival outcomes in gastric cancer patients.By analyzing signaling pathways and biological functions correlated with AKGI, we elucidated the regulatory mechanisms and biological roles of α-KG in gastric cancer. These insights were validated through cellular experiments, where α-KG treatment was shown to significantly inhibit gastric cancer cell proliferation, migration, and invasion.Taken together, our data demonstrate AKGI offers a valuable framework for advancing our understanding of the role and mechanisms of α-KG in gastric cancer.
2025-01-03 | GSE285448 | GEO
Project description:Activation of macrophages by inflammatory stimuli leads to reprogramming of mitochondrial metabolism to support the production of pro-inflammatory cytokines. Hallmarks of this metabolic rewiring are downregulation of α-ketoglutarate formation via isocitrate dehydrogenase (IDH) and accumulation of glutamine-derived succinate, which enhances the inflammatory response via the activity of succinate dehydrogenase (SDH). Here, we identify the nuclear receptor Nur77 (Nr4a1) as a key regulator of the pro-inflammatory metabolic switch in macrophages. Nur77-deficient macrophages fail to downregulate IDH expression and accumulate higher levels of succinate and other downstream TCA cycle metabolites in response to an inflammatory stimulus. Consequently, these macrophages produce more nitric oxide and pro-inflammatory cytokines in an SDH-dependent manner. In vivo, bone marrow Nur77 deficiency exacerbates atherosclerosis development and leads to increased systemic succinate levels. In conclusion, Nur77 supports an anti-inflammatory metabolic state in macrophages that protects against chronic inflammatory diseases such as atherosclerosis.
2018-08-21 | GSE102359 | GEO